|
Glycogen Storage Disease
|
0.300 |
Biomarker
|
group |
GENOMICS_ENGLAND |
Advantages and pitfalls of an extended gene panel for investigating complex neurometabolic phenotypes.
|
27604308 |
2016 |
|
Bipolar Disorder
|
0.300 |
Biomarker
|
disease |
PSYGENET |
In the present study, we investigated the mRNA expression levels of HIF-1 (α and β) and its target genes (VEGF, GLUT1, PGK1, PFKFB3, and LDHA) in the peripheral white blood cells of patients with major depressive disorder (MDD) and bipolar disorder (BPD).
|
23333658 |
2013 |
|
Unipolar Depression
|
0.300 |
Biomarker
|
disease |
PSYGENET |
The alteration of hypoxia inducible factor-1 (HIF-1) and its target genes in mood disorder patients.
|
23333658 |
2013 |
|
Mood Disorders
|
0.300 |
Biomarker
|
group |
PSYGENET |
The alteration of hypoxia inducible factor-1 (HIF-1) and its target genes in mood disorder patients.
|
23333658 |
2013 |
|
Cardiomyopathies, Primary
|
0.300 |
Biomarker
|
group |
CTD_human |
Protection against doxorubicin cardiomyopathy in rats: role of phosphodiesterase inhibitors type 4.
|
15231041 |
2004 |
|
Myocardial Diseases, Secondary
|
0.300 |
Biomarker
|
group |
CTD_human |
Protection against doxorubicin cardiomyopathy in rats: role of phosphodiesterase inhibitors type 4.
|
15231041 |
2004 |
|
Cardiomyopathies
|
0.300 |
Biomarker
|
group |
CTD_human |
Protection against doxorubicin cardiomyopathy in rats: role of phosphodiesterase inhibitors type 4.
|
15231041 |
2004 |
|
Myocardial Infarction
|
0.300 |
Biomarker
|
disease |
CTD_human |
Effect of very early intravenous streptokinase infusion in patients with evolving myocardial infarction.
|
3279722 |
1988 |
|
Glycogen Storage Disease
|
0.300 |
Biomarker
|
group |
GENOMICS_ENGLAND |
Estimation of the gene frequency of lactate dehydrogenase subunit deficiencies.
|
6517049 |
1984 |
|
Hyperglycemia
|
0.210 |
AlteredExpression
|
disease |
BEFREE |
The accumulation of HIF-1α induced by hyperglycemia increases LDHA activity and HK2, PFKP expression, thereby promoting pancreatic glycolysis to facilitate cancer progression.
|
31241439 |
2019 |
|
Hyperglycemia
|
0.210 |
Biomarker
|
disease |
RGD |
Critical reduction in beta-cell mass results in two distinct outcomes over time. Adaptation with impaired glucose tolerance or decompensated diabetes.
|
12438314 |
2003 |
|
Neoplasms, Experimental
|
0.200 |
Biomarker
|
phenotype |
RGD |
Tumor induction by the c-Myc target genes rcl and lactate dehydrogenase A.
|
11085542 |
2000 |
|
Muscular stiffness
|
0.110 |
Biomarker
|
phenotype |
BEFREE |
Otherwise, patients with a lactate dehydrogenase M-subunit deficiency do not show muscle stiffness and myoglobinuria under ordinary circumstances.
|
3383424 |
1988 |
|
Muscular stiffness
|
0.110 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Furthermore, we discuss experimental compounds that target glycolytic metabolism, such as LDH-A inhibitors, and their potential to improve current and experimental therapeutics against metastatic tumors.
|
31445217 |
2020 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, the LDHA-lowering agent vitamin C can be a potential approach for combating stress-associated breast cancer.
|
30688660 |
2019 |
|
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The results showed that MTA1 expression is positively correlated with the LDHA expression levels in breast cancer patients.
|
31570164 |
2019 |
|
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here, we showed that BA could inhibit aerobic glycolysis activity in breast cancer cell lines MCF-7 and MDA-MB-231 by hampering lactate production, glucose uptake and extracellular acidification rate (ECAR), as well as suppressing aerobic glycolysis-related proteins including c-Myc, lactate dehydrogenase A (LDH-A) and p-PDK1/PDK1 (pyruvate dehydrogenase kinase 1).
|
30684465 |
2019 |
|
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, our findings showed that repression of LDHA induced by wt-p53 blocks tumor growth and invasion through downregulation of aerobic glycolysis in breast cancer, providing new insights into the mechanism by which p53 contributes to the development and progression of breast cancer.
|
30618169 |
2019 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Study shows that signal transducer and activator of transcription 3 (STAT3) can increase the Warburg effect by stimulating hexokinase 2 in breast cancer and upregulate lactate dehydrogenase A and pyruvate dehydrogenase kinase 1 in myeloma.
|
31086462 |
2019 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
In total, targeting LDHA opened a novel strategy to interrupt autophagy and tamoxifen resistance in breast cancer.
|
30878502 |
2019 |
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Clinical, translational and experimental data supporting the uniqueness of the LDHA gene and its product LDH5 isoenzyme are summarized and future directions for a metabolic treatment of cancer are highlighted.
|
29913092 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Reprogrammed glucose metabolism is one of the hallmarks of cancer, and increased expression of key glycolytic enzymes, such as pyruvate kinase M2 (PKM2) and lactate dehydrogenase A (LDHA), has been associated with poor prognosis in various malignancies.
|
31527446 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Lactate dehydrogenase A (LDHA) is an important enzyme responsible for cancer growth and energy metabolism in various cancers via the aerobic glycolytic pathway.
|
31324019 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Taken together, our data suggest that NDRG2 plays an important role in inhibiting the Warburg effect and the malignant growth of HCC via LDHA.
|
31523182 |
2019 |